About

About
The DS management team has both a strong background in developing drugs for the market and experience in building life science companies.

Pipeline

Pipeline
DS Biopharma have two novel assets in various stages of clinical and pre-clinical development and intend to add more bioactive lipids to the current portfolio in the coming years.

Investors

Investors
To date, DS Biopharma have been funded privately.

Latest News

October 18, 2018

Oral DS107 found to reverse the molecular signature of moderate to severe atopic dermatitis patients in a phase 2 trial

Dublin, Ireland, October 18th 2018 – DS Biopharma (DS), a privately held biopharmaceutical company, today announced that oral treatment with DS107 reversed the molecular signature of […]
October 3, 2018

DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis

DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis Dublin, Ireland, October 3rd 2018 […]

Join our mailing list

Connect with us